Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines
ConditionGlabellar Lines
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age19-65
SponsorDaewoong Pharmaceutical Co. LTD.
About this trial
To evaluate the efficacy and safety of DWP712 Inj. in Subjects with Moderate to Severe Glabellar Lines
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
None
Trial design
Design model
Parallel
Treatments tested in this trial
DWP712 inj.
Biological/VaccineClostridium botulinum Toxin
Botox® 100 Units
Biological/VaccineClostridium botulinum Toxin
Treatment groups
324 Participants
are divided into 2 treatment groupsGroup A: DWP712 inj.Experimental treatment 1 intervention
Group B: Botox® 100 UnitsActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Percentage of subjects with glabellar line improvement* rate at maximum frown based on the investigator's on-site assessment at 4 weeks after IP administration
Improvement means FWS grade of "0" or "1" with a ≥2-point improvement from baseline
Time frame
At 4 weeks after IP administrationSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: